EUVIMEDEUVIMED entdecken
Crossref

SA13 SHOULD PHASE 2 STUDIES BE ROUTINELY EXCLUDED IN COMPARATIVE EFFECTIVENESS ITCS?

Tim Disher

Value in Health · 2026-06 · 29 (6) · S441

DOI: 10.1016/j.jval.2026.03.2181 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Value in Health, 2026-06. Verfasst von Tim Disher.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Disher, T. (2026). SA13 SHOULD PHASE 2 STUDIES BE ROUTINELY EXCLUDED IN COMPARATIVE EFFECTIVENESS ITCS?. Value in Health, 29(6), S441. https://doi.org/10.1016/j.jval.2026.03.2181

Vancouver

Disher T. SA13 SHOULD PHASE 2 STUDIES BE ROUTINELY EXCLUDED IN COMPARATIVE EFFECTIVENESS ITCS?. Value in Health. 2026;29(6):S441. doi:10.1016/j.jval.2026.03.2181

BibTeX
@article{Disher2026,
  author = {Disher, Tim},
  title = {SA13 SHOULD PHASE 2 STUDIES BE ROUTINELY EXCLUDED IN COMPARATIVE EFFECTIVENESS ITCS?},
  journal = {Value in Health},
  year = {2026},
  volume = {29},
  number = {6},
  pages = {S441},
  doi = {10.1016/j.jval.2026.03.2181}
}
Kostenlos starten →